These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10801249)

  • 41. Effect of diabetes on the morphine-induced inhibition of gastrointestinal transit.
    Kamei J; Ohsawa M; Misawa M; Nagase H; Kasuya Y
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):165-9. PubMed ID: 7796321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine.
    Hawkes ND; Richardson C; Evans BK; Rhodes J; Lewis SJ; Thomas GA
    Aliment Pharmacol Ther; 2001 May; 15(5):625-30. PubMed ID: 11328255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral controlled-release morphine and gut function: a study in volunteers.
    Clyburn PA; Rosen M
    Eur J Anaesthesiol; 1989 Sep; 6(5):347-53. PubMed ID: 2676529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of methylnaltrexone and naloxone on esophageal motor function in man.
    Scarpellini E; Pauwels A; Vos R; Rommel N; Tack J
    Neurogastroenterol Motil; 2017 Mar; 29(3):. PubMed ID: 28110513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of naloxone-3-glucuronide on colonic transit time in healthy men after acute morphine administration: a placebo-controlled double-blinded crossover preclinical volunteer study.
    Netzer P; Sendensky A; Wissmeyer MP; Baumeler S; Batista C; Scheurer U; Krause T; Reber P; Brenneisen R
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1334-41. PubMed ID: 18808445
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Subcutaneous methylnaltrexone for opioid-induced constipation in advanced-illness patients with or without active cancer.
    Chamberlain BH; Rhiner M; Slatkin NE; Stambler N; Israel RJ
    Pain Manag; 2020 Mar; 10(2):73-84. PubMed ID: 31951150
    [No Abstract]   [Full Text] [Related]  

  • 47. Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats.
    Gmerek DE; Cowan A; Woods JH
    J Pharmacol Exp Ther; 1986 Jan; 236(1):8-13. PubMed ID: 3941402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of the peripherally acting μ-opioid receptor antagonist methylnaltrexone on acute pancreatitis severity: study protocol for a multicentre double-blind randomised placebo-controlled interventional trial, the PAMORA-AP trial.
    Knoph CS; Cook ME; Fjelsted CA; Novovic S; Mortensen MB; Nielsen LBJ; Hansen MB; Frøkjær JB; Olesen SS; Drewes AM
    Trials; 2021 Dec; 22(1):940. PubMed ID: 34924020
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of remifentanil on pharyngeal swallowing and esophageal motility: no impact of different bolus volumes and partial antagonism by methylnaltrexone.
    Cajander P; Omari T; Cock C; Magnuson A; Scheinin M; Savilampi J
    Am J Physiol Gastrointest Liver Physiol; 2021 Oct; 321(4):G367-G377. PubMed ID: 34261364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of remifentanil on the esophagogastric junction and swallowing.
    Savilampi J; Ahlstrand R; Magnuson A; Wattwil M
    Acta Anaesthesiol Scand; 2013 Sep; 57(8):1002-9. PubMed ID: 23713743
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peripheral effects of opioids in a model of chronic intestinal inflammation in mice.
    Puig MM; Pol O
    J Pharmacol Exp Ther; 1998 Dec; 287(3):1068-75. PubMed ID: 9864294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methylnaltrexone reduced body weight gain in ob/ob mice.
    Yuan CS; Wang CZ; Attele A; Zhang L
    J Opioid Manag; 2009; 5(4):213-8. PubMed ID: 19736901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro evaluation of the effect of the opioid antagonist N-methylnaltrexone on motility of the equine jejunum and pelvic flexure.
    van Hoogmoed LM; Boscan PL
    Equine Vet J; 2005 Jul; 37(4):325-8. PubMed ID: 16028621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study.
    Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):434-41. PubMed ID: 27137715
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methylnaltrexone methobromide: the first peripherally active, centrally inactive opioid receptor-antagonist.
    Guay DR
    Consult Pharm; 2009 Mar; 24(3):210-26. PubMed ID: 19555136
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study.
    Foss JF; O'Connor MF; Yuan CS; Murphy M; Moss J; Roizen MF
    J Clin Pharmacol; 1997 Jan; 37(1):25-30. PubMed ID: 9048269
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans.
    Jones HE; Johnson RE; Fudala PJ; Henningfield JE; Heishman SJ
    Drug Alcohol Depend; 2000 Jul; 60(1):29-37. PubMed ID: 10821987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quinine-induced inhibition of gastrointestinal transit in mice: possible involvement of endogenous opioids.
    Santos FA; Rao VS
    Eur J Pharmacol; 1999 Jan; 364(2-3):193-7. PubMed ID: 9932723
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
    Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
    Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of an enteric-coated naproxen pellet formulation.
    Hardy JG; Lamont GL; Evans DF; Haga AK; Gamst ON
    Aliment Pharmacol Ther; 1991 Feb; 5(1):69-75. PubMed ID: 1932483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.